Quantcast

Oligomerix, Inc to Participate in the NIH Innovation Zone at the 2019 BIO International Convention

NEW YORK–(BUSINESS WIRE)–Oligomerix, Inc., a privately held company pioneering the development of
tau oligomer inhibitors for Alzheimer’s disease (AD) and related
neurodegenerative disorders, announced today the company is one of the
select group of NIH SBIR awardees chosen to participate in the NIH Innovation
Zone
at the 2019 BIO International Convention. The conference will
take place June 3-6, 2019 at the Philadelphia Convention Center.

Details are as follows:

Exhibit at NIH Innovation Zone
Dates: June 4-6, 2019
Location:
Booth 4270, Kiosk IZ-29

Company Presentation
Date: June 3, 2019
Time: 3:45 pm
Location:
BIO Business Forum, Theater 3

“We are grateful that the NIH selected Oligomerix to participate in the
Innovation Zone at BIO and are excited to be one of the few companies
chosen for a presentation,” said James Moe, Ph.D., MBA, President and
CEO of Oligomerix. “We look forward to advancing our partnering
discussions and explaining our core technology’s unique approach to
targeting tau oligomers.”

Through the Small Business Innovation Research and Small Business
Technology Transfer (SBIR/STTR) program, the National Institutes of
Health (NIH) has funded many promising technologies and is committed to
assisting its grantees/awardees further on their path to
commercialization. This year NIH partnered with BIO to provide select
SBIR/STTR awardees with premier visibility at the BIO International
Convention, providing each company with access to business development
executives from around the globe, as well as investors.

The upcoming 2019
BIO International Convention
(June 3-6 in Philadelphia, PA) features
more than 16,000 attendees in the life science and application areas,
including drug discovery, biomanufacturing, genomics, biofuels,
nanotechnology and cell therapy. The event offers opportunities to
partner, learn, and network with global biotech and pharma leaders.

This year, there will be a high profile, 6,300 square foot area of the
Exhibition floor branded as the Innovation Zone, a turn-key exhibit
space dedicated to showcasing 80 NIH SBIR/STTR awardees.

About Oligomerix, Inc.

Oligomerix is an early-stage biotechnology company focused on
discovering and developing novel, small-molecule tau oligomer inhibitors
for Alzheimer’s disease (AD) and related neurodegenerative diseases with
tau pathology. Oligomerix’ drug discovery platform has identified a
pipeline of novel, central nervous system (CNS), small molecule lead
compounds for neurodegenerative diseases such as AD. The leads were
designed to inhibit tau oligomer formation at the beginning of the
aggregation process and in vivo proof-of-concept has been achieved in an
animal model best representing tau aggregation in AD. The company’s lead
program targeting AD has initiated IND-enabling studies. The NYC based
company is located at the Ullmann Research Center for Health Sciences
within the Albert Einstein College of Medicine and has received
considerable support from the National Institute on Aging of the
National Institute of Health (NIH). Oligomerix is seeking strategic
partners to support the acceleration and advancement of these important
programs. For more information about Oligomerix, please visit www.oligomerix.com.

Contacts

Company Contact:
Jack Pasini
Chief Commercial Officer
917-912-4088
[email protected]

James Moe, Ph.D., MBA
President and CEO
212-568-0365
[email protected]

Media Contact:
Michelle Linn
Bioscribe
774-696-3803
[email protected]

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.